# Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

> **NCT01982292** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 321 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** RLX030 (serelaxin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01982292
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2016-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982292, "Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01982292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*